Related Experiment Video
Updated: Aug 24, 2026

A High-content Assay for Monitoring AMPA Receptor Trafficking
Published on: January 28, 2019
Modulation of Na(+),K(+) pumping and neurotransmitter uptake by beta-amyloid
1Shanghai Institute of Biochemistry and Cell Biology, 320 YueYang Road, 200031 Shanghai, China.
Abstract:
Micromolar concentrations of beta-amyloid (Abeta), a 40/42-amino-acid-long proteolytic fragment (Abeta(1-40/42)) of the amyloid precursor protein, was shown previously to play a crucial role in pathogenesis of Alzheimer's disease. We used the Xenopus oocyte expression system to investigate specific effects of micromolar concentrations of Abeta(1-42) on the neurotransmitter transporters for gamma-aminobutyric acid (GABA), GAT1, and for the excitatory amino acid glutamate, EAAC1, which are driven by the transmembrane Na(+) gradient that is regulated by the Na(+),K(+)-ATPase. Brief treatment with Abeta(1-42), up to 80 min, leads to a significant inhibition of ion translocation by the Na(+),K(+)-ATPase (30-40%); also glutamate uptake is inhibited (20%) while GABA uptake is not affected. Since reduced glutamate uptake will result in elevated, neurotoxic concentrations of extracellular glutamate, we investigated the effects of Abeta(1-42) and the smaller fragments, Abeta(12-28) and Abeta(25-35), on EAAC1 in more detail. Prolonged incubation in 1 microM Abeta(1-42) leads to further, strong inhibition of glutamate uptake and EAAC1-mediated current (after 4 h inhibition amounts to more than 80%). Abeta(12-28) is less effective with 50% inhibition after 4 h of incubation at 20 microM. Abeta(1-42) and Abeta(12-28) affect EAAC1-mediated current to a similar extent as the rate of glutamate uptake. The effects on EAAC1-mediated current are irreversible if Abeta were applied for longer time periods. Peptides directly microinjected into the oocyte are ineffective suggesting that the observed effect were mediated by extracellular proteins. Abeta(25-35) hardly affects EAAC1-mediated current or glutamate uptake. The results demonstrate that Abeta specifically inhibits the Na(+),K(+) pump and EAAC1. The domain between amino acids 12 and 28 of Abeta seems to play a crucial role for inhibition of EAAC1. The inhibition of EAAC1 by neurotoxic, elevated extracellular glutamate levels may contribute to Alzheimer's pathogenesis.
Insights
Beta-amyloid (Abeta) inhibits the Na(+),K(+)-ATPase and glutamate transporters (EAAC1) in Alzheimer's disease research. This inhibition of glutamate uptake may contribute to neurotoxicity and disease progression.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Alzheimer's disease pathogenesis involves beta-amyloid (Abeta) peptides.
- Neurotransmitter transporters, like EAAC1 for glutamate and GAT1 for GABA, are crucial for neuronal function.
- These transporters rely on the Na(+),K(+)-ATPase for maintaining ion gradients.
Purpose of the Study:
- To investigate the specific effects of micromolar concentrations of Abeta(1-42) on GABA (GAT1) and glutamate (EAAC1) transporters.
- To determine the impact of Abeta on the Na(+),K(+)-ATPase activity.
- To identify the specific Abeta fragments responsible for inhibiting EAAC1.
Main Methods:
- Xenopus oocyte expression system used to study transporter function.
- Measurement of ion translocation by Na(+),K(+)-ATPase.
- Assay of glutamate and GABA uptake rates and transporter-mediated currents.
- Incubation with various Abeta fragments (Abeta(1-42), Abeta(12-28), Abeta(25-35)) at different concentrations and durations.
Main Results:
- Brief Abeta(1-42) treatment inhibited Na(+),K(+)-ATPase activity (30-40%) and glutamate uptake (20%), with no effect on GABA uptake.
- Prolonged incubation with Abeta(1-42) strongly inhibited glutamate uptake and EAAC1 current (>80% after 4h).
- The Abeta(12-28) fragment showed partial inhibition (50% after 4h at 20 microM), while Abeta(25-35) had minimal effect.
- Inhibition of EAAC1 was irreversible with prolonged Abeta exposure and mediated by extracellularly applied peptides.
Conclusions:
- Abeta specifically inhibits the Na(+),K(+)-ATPase and the glutamate transporter EAAC1.
- The amino acid domain 12-28 of Abeta is critical for EAAC1 inhibition.
- Inhibition of EAAC1, leading to elevated extracellular glutamate, may contribute to Alzheimer's disease neurotoxicity.
More Related Videos
09:52Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System
Published on: December 28, 2017
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Related Concept Videos
Neurochemical Transmission: Sites of Drug Action
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Drugs Affecting Neurotransmitter Release or Uptake
Drugs Affecting Neurotransmitter Synthesis
Excitatory and Inhibitory Effects of Neurotransmitters
Adrenergic Neurons: Neurotransmission
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...